P triazole tetraiodothyroacetic acid - NanoPharmaceuticals
Alternative Names: P-TAT; P-triazole tetraiodothyroacetic acidLatest Information Update: 24 Mar 2022
At a glance
- Originator NanoPharmaceuticals
- Class Anti-inflammatories; Macromolecular substances; Skin disorder therapies; Triazoles
- Mechanism of Action Angiogenesis inhibitors; Chemokine inhibitors; Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis; Rosacea
Most Recent Events
- 14 Mar 2022 Preclinical trials in Psoriasis in USA (Topical) prior to March 2022 (NanoPharmaceuticals pipeline, March 2022)
- 14 Mar 2022 Preclinical trials in Rosacea in USA (Topical) prior to March 2022 (NanoPharmaceuticals pipeline, March 2022)